Intelligence for Nephrologists

Active Clinical Trials in
Nephrology in Brazil

Up-to-date overview of nephrology clinical trials recruiting patients in Brazil — automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centres.

11
Active trials
55
Sites in Brazil
6
Indications covered
Carregando mapa…

11 studies found

Fase 2Glomeruloesclerose Focal e Segmentar (FSGS)Doença de Lesões Mínimas🇧🇷 4 sites in Brazil

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Sanofi

📍 Botucatu, São Paulo👥 84 participants📅 Completion: 2026-12
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Granulomatose Eosinofílica com PoliangiiteSíndrome Hipereosinofílica🇧🇷 1 site in Brazil

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

AstraZeneca

📍 São Paulo👥 14 participants📅 Completion: 2028-02
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Granulomatose com PoliangiitePoliangeíte Microscópica🇧🇷 4 sites in Brazil

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Novartis Pharmaceuticals

📍 Barretos, Salvador, São Paulo👥 126 participants📅 Completion: 2029-06
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Nefropatia por IgA🇧🇷 7 sites in Brazil

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Biogen

📍 Belo Horizonte, Caxias do Sul, Juiz de Fora, Porto Alegre, São Paulo👥 454 participants📅 Completion: 2027-05
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Nefropatia Membranosa Primária🇧🇷 7 sites in Brazil

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Biogen

📍 Belo Horizonte, Porto Alegre, Ribeirão Preto, São José do Rio Preto, São Paulo👥 180 participants📅 Completion: 2030-01
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Nefropatia Membranosa Primária🇧🇷 6 sites in Brazil

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Climb Bio, Inc.

📍 Belo Horizonte, Minas Gerais, Pernambuco, Porto Alegre, São Paulo👥 45 participants📅 Completion: 2027-10
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Nefropatia por IgA🇧🇷 4 sites in Brazil

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Novartis Pharmaceuticals

📍 Botucatu, Natal, Recife, Serra👥 32 participants📅 Completion: 2030-07
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Nefropatia Membranosa Primária🇧🇷 4 sites in Brazil

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Alexion Pharmaceuticals, Inc.

📍 Recife, Salvador, São Paulo👥 30 participants📅 Completion: 2027-07
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Vasculite Associada a ANCA🇧🇷 7 sites in Brazil

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Alexion Pharmaceuticals, Inc.

📍 Barretos, Belo Horizonte, Porto Alegre, Recife, São Paulo👥 75 participants📅 Completion: 2027-10
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2, Fase 3Nefropatia Membranosa Primária🇧🇷 5 sites in Brazil

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Vertex Pharmaceuticals Incorporated

📍 Belo Horizonte, Porto Alegre, Recife, Salvador, São Paulo👥 176 participants📅 Completion: 2028-12
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Glomeruloesclerose Focal e Segmentar (FSGS)🇧🇷 6 sites in Brazil

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Boehringer Ingelheim

📍 Campinas, Fortaleza, Porto Alegre, São Paulo👥 286 participants📅 Completion: 2028-12
View details →Refer patient →ClinicalTrials.gov ↗

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Contact us →